North America PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Country and Growth Forecast, 2024 - 2031

The North America PARP Inhibitor Biomarkers Market would witness market growth of 7.8% CAGR during the forecast period (2024-2031).

The US market dominated the North America PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $479.7 Million by 2031. The Canada market is experiencing a CAGR of 10.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 9.3% during (2024 - 2031).

The market refers to the sector within the healthcare industry focused on developing, commercializing, and utilizing biomarker testing technologies and services specifically related to PARP (poly (ADP-ribose) polymerase) inhibitors.

Moreover, these are a class of anticancer drugs that target enzymes involved in DNA repair processes, particularly in cancer cells with deficiencies in other DNA repair pathways, such as BRCA1 and BRCA2 mutations.

Higher healthcare expenditure may result in increased funding for healthcare infrastructure, including diagnostic laboratories and testing facilities in Canada. This can lead to improved access to biomarker testing services, including it, for patients across Canada. Increased availability of biomarker testing can facilitate earlier detection of biomarker-defined patient populations eligible for this therapy, thereby driving market growth.

Free Valuable Insights: The PARP Inhibitor Biomarkers Market is Predict to reach USD 1.6 Billion by 2031, at a CAGR of 8.3%

Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• Myriad Genetics, Inc.
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• NeoGenomics Laboratories
• Qiagen N.V
• Agilent Technologies, Inc.
• Merck KGaA
• Bayer AG
• AstraZeneca PLC
• GlaxoSmithKline PLC (GSK)

North America PARP Inhibitor Biomarkers Market Report Segmentation

By Product

• Kits
• Assays

By Application

• Breast Cancer
• Ovarian Cancer
• Others

By Services

• BRCA 1 & 2 Testing
• HRD Testing
• HRR Testing
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America PARP Inhibitor Biomarkers Market, by Product
1.4.2 North America PARP Inhibitor Biomarkers Market, by Application
1.4.3 North America PARP Inhibitor Biomarkers Market, by Services
1.4.4 North America PARP Inhibitor Biomarkers Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis

Chapter 4. North America PARP Inhibitor Biomarkers Market by Product
4.1 North America Kits Market by Region
4.2 North America Assays Market by Region

Chapter 5. North America PARP Inhibitor Biomarkers Market by Application
5.1 North America Breast Cancer Market by Country
5.2 North America Ovarian Cancer Market by Country
5.3 North America Others Market by Country

Chapter 6. North America PARP Inhibitor Biomarkers Market by Services
6.1 North America BRCA 1 & 2 Testing Market by Country
6.2 North America HRD Testing Market by Country
6.3 North America HRR Testing Market by Country
6.4 North America Others Market by Country

Chapter 7. North America PARP Inhibitor Biomarkers Market by Country
7.1 US PARP Inhibitor Biomarkers Market
7.1.1 US PARP Inhibitor Biomarkers Market by Product
7.1.2 US PARP Inhibitor Biomarkers Market by Application
7.1.3 US PARP Inhibitor Biomarkers Market by Services
7.2 Canada PARP Inhibitor Biomarkers Market
7.2.1 Canada PARP Inhibitor Biomarkers Market by Product
7.2.2 Canada PARP Inhibitor Biomarkers Market by Application
7.2.3 Canada PARP Inhibitor Biomarkers Market by Services
7.3 Mexico PARP Inhibitor Biomarkers Market
7.3.1 Mexico PARP Inhibitor Biomarkers Market by Product
7.3.2 Mexico PARP Inhibitor Biomarkers Market by Application
7.3.3 Mexico PARP Inhibitor Biomarkers Market by Services
7.4 Rest of North America PARP Inhibitor Biomarkers Market
7.4.1 Rest of North America PARP Inhibitor Biomarkers Market by Product
7.4.2 Rest of North America PARP Inhibitor Biomarkers Market by Application
7.4.3 Rest of North America PARP Inhibitor Biomarkers Market by Services

Chapter 8. Company Profiles
8.1 Myriad Genetics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.2 Thermo Fisher Scientific, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 SWOT Analysis
8.3 Illumina, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segment and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Neogenomics, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Qiagen N.V.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Agilent Technologies, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Merck KGaA
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 AstraZeneca PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis

TABLE 1 North America PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 2 North America PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 3 North America PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 4 North America PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 5 North America Kits Market by Region, 2020 - 2023, USD Million
TABLE 6 North America Kits Market by Region, 2024 - 2031, USD Million
TABLE 7 North America Assays Market by Region, 2020 - 2023, USD Million
TABLE 8 North America Assays Market by Region, 2024 - 2031, USD Million
TABLE 9 North America PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 10 North America PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 11 North America Breast Cancer Market by Country, 2020 - 2023, USD Million
TABLE 12 North America Breast Cancer Market by Country, 2024 - 2031, USD Million
TABLE 13 North America Ovarian Cancer Market by Country, 2020 - 2023, USD Million
TABLE 14 North America Ovarian Cancer Market by Country, 2024 - 2031, USD Million
TABLE 15 North America Others Market by Country, 2020 - 2023, USD Million
TABLE 16 North America Others Market by Country, 2024 - 2031, USD Million
TABLE 17 North America PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 18 North America PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 19 North America BRCA 1 & 2 Testing Market by Country, 2020 - 2023, USD Million
TABLE 20 North America BRCA 1 & 2 Testing Market by Country, 2024 - 2031, USD Million
TABLE 21 North America HRD Testing Market by Country, 2020 - 2023, USD Million
TABLE 22 North America HRD Testing Market by Country, 2024 - 2031, USD Million
TABLE 23 North America HRR Testing Market by Country, 2020 - 2023, USD Million
TABLE 24 North America HRR Testing Market by Country, 2024 - 2031, USD Million
TABLE 25 North America Others Market by Country, 2020 - 2023, USD Million
TABLE 26 North America Others Market by Country, 2024 - 2031, USD Million
TABLE 27 North America PARP Inhibitor Biomarkers Market by Country, 2020 - 2023, USD Million
TABLE 28 North America PARP Inhibitor Biomarkers Market by Country, 2024 - 2031, USD Million
TABLE 29 US PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 30 US PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 31 US PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 32 US PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 33 US PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 34 US PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 35 US PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 36 US PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 37 Canada PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 38 Canada PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 39 Canada PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 40 Canada PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 41 Canada PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 42 Canada PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 43 Canada PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 44 Canada PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 45 Mexico PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 46 Mexico PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 47 Mexico PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 48 Mexico PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 49 Mexico PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 50 Mexico PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 51 Mexico PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 52 Mexico PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 53 Rest of North America PARP Inhibitor Biomarkers Market, 2020 - 2023, USD Million
TABLE 54 Rest of North America PARP Inhibitor Biomarkers Market, 2024 - 2031, USD Million
TABLE 55 Rest of North America PARP Inhibitor Biomarkers Market by Product, 2020 - 2023, USD Million
TABLE 56 Rest of North America PARP Inhibitor Biomarkers Market by Product, 2024 - 2031, USD Million
TABLE 57 Rest of North America PARP Inhibitor Biomarkers Market by Application, 2020 - 2023, USD Million
TABLE 58 Rest of North America PARP Inhibitor Biomarkers Market by Application, 2024 - 2031, USD Million
TABLE 59 Rest of North America PARP Inhibitor Biomarkers Market by Services, 2020 - 2023, USD Million
TABLE 60 Rest of North America PARP Inhibitor Biomarkers Market by Services, 2024 - 2031, USD Million
TABLE 61 Key Information – Myriad Genetics, Inc.
TABLE 62 Key Information – Thermo Fisher Scientific, Inc.
TABLE 63 key information – Illumina, Inc.
TABLE 64 Key Information – neogenomics, inc.
TABLE 65 Key Information – Qiagen N.V.
TABLE 66 key Information – Agilent Technologies, Inc.
TABLE 67 key Information – Merck KGaA
TABLE 68 Key Information – Bayer AG
TABLE 69 Key Information – AstraZeneca PLC
TABLE 70 Key Information – GlaxoSmithKline PLC

List of Figures
FIG 1 Methodology for the research
FIG 2 North America PARP Inhibitor Biomarkers Market, 2020 - 2031, USD Million
FIG 3 Key Factors Impacting PARP Inhibitor Biomarkers Market
FIG 4 Porter’s Five Forces Analysis – PARP Inhibitor Biomarkers Market
FIG 5 North America PARP Inhibitor Biomarkers Market share by Product, 2023
FIG 6 North America PARP Inhibitor Biomarkers Market share by Product, 2031
FIG 7 North America PARP Inhibitor Biomarkers Market by Product, 2020 - 2031, USD Million
FIG 8 North America PARP Inhibitor Biomarkers Market share by Application, 2023
FIG 9 North America PARP Inhibitor Biomarkers Market share by Application, 2031
FIG 10 North America PARP Inhibitor Biomarkers Market by Application, 2020 - 2031, USD Million
FIG 11 North America PARP Inhibitor Biomarkers Market share by Services, 2023
FIG 12 North America PARP Inhibitor Biomarkers Market share by Services, 2031
FIG 13 North America PARP Inhibitor Biomarkers Market by Services, 2020 - 2031, USD Million
FIG 14 North America PARP Inhibitor Biomarkers Market share by Country, 2023
FIG 15 North America PARP Inhibitor Biomarkers Market share by Country, 2031
FIG 16 North America PARP Inhibitor Biomarkers Market by Country, 2020 - 2031, USD Million
FIG 17 SWOT Analysis: Thermo Fisher Scientific, Inc.
FIG 18 Swot Analysis: Illumina, Inc.
FIG 19 Swot Analysis: Qiagen N.V.
FIG 20 Swot Analysis: Agilent Technologies, Inc.
FIG 21 Swot Analysis: Merck KGaA
FIG 22 Swot Analysis: Bayer AG
FIG 23 SWOT Analysis: AstraZeneca PLC
FIG 24 SWOT Analysis: GlaxoSmithKline PLC